6872-27-1

Usage

InChI:InChI=1/C21H25NO4/c1-23-18-8-13-5-6-22-12-15-10-20(25-3)19(24-2)9-14(15)7-17(22)16(13)11-21(18)26-4/h8-11,17H,5-7,12H2,1-4H3

Upstream product

• 42337-61-1 C₂₁H₂₃NO₅ 
• 52050-59-6 2,3,9,10-tetramethoxy-8-oxoberbine 
• 16135-49-2 N-<2-(3,4-dimethoxyphenyl)-ethyl>-(4,5-dimethoxy-2-hydroxymethyl)-phenylacetamide 
• 106544-61-0 2-(4,5-dimethoxy-2-((trimethylsilyl)methyl)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinolinium perchlorate 
• 101481-11-2 Phosphoric acid diethyl ester 2,3,10,11-tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinolin-12-yl ester 
• 10211-78-6 8-oxypseudopalmatine 
• 50-00-0 formaldehyd 
• 148679-68-9 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-2-(2-phenylsulfanyl-ethyl)-1,2,3,4-tetrahydro-isoquinoline 
• 31756-16-8 6,7-dimethoxy-2-veratryl-3,4-dihydro-isoquinolinium; chloride 
• 7306-46-9 4-chloromethyl-1,2-dimethoxy-benzene 
• 53207-00-4 1-bromo-2-(bromomethyl)-4,5-dimethoxybenzene 
• 59444-59-6 (+/-)-1-(2-bromo-4,5-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 4230-93-7 1,2-dimethoxy-4-(2-nitro-vinyl)-benzene 
• 13074-31-2 Tetrahydropapaverine 

Downstream Products

• 57129-74-5 (+/-)-N-methylxylopinine iodide 
• 52194-51-1 (+/-)-Xylopinin-trans-methiodid 
• 120021-26-3 3-(2-vinyl-4,5-dimethoxyphenyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 6899-65-6 (+/-)-O-methylcorytenchirine 
• 19716-66-6 pseudopalmatine 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

One-pot tandem route to fused indolizidines and quinolizidines: Application in the synthesis of alkaloids and bioactive compounds

Fused indolizidines and quinolizidines are important skeletons in a variety of natural products and pharmacologically important compounds. A one-pot tandem route from amide to fused indolizidines and quinolizidines is disclosed. This method is conducted in mild conditions and shows well tolerance of functional groups. It is also easy to be scaled up to gram scale and can be applied smoothly to the total synthesis of alkaloids such as (±)-crispine A, (±)-xylopinine, (±)-desbromoarborescidine A, (±)-harmicine and other bioactive substances.

Stereoselective construction of a berberine C-8 benzyl group for the synthesis of javaberine derivatives

Diastereoselective synthesis of 8-benzyltetrahydroprotoberberines was examined. Although Stevens rearrangement of N-benzylxylopinine resulted in poor yield and diastereoselectivity, benzylation of tetracyclic iminium successfully gave H8-H14 trans-benzyltetrahydroprotoberberines with high stereoselectivity.

Development of Pd(OAc)2-catalyzed tandem oxidation of C[sbnd]N, C[sbnd]C, and C(sp3)–H bonds: Concise synthesis of 1-aroylisoquinoline, oxoaporphine, and 8-oxyprotoberberine alkaloids

A catalytic tandem oxidation of C[sbnd]N, C[sbnd]C, and C(sp3)–H bonds is developed. This tandem oxidation is applied to two-step total syntheses of papaveraldine and pulcheotine A. Additionally, the total synthesis of liriodenine is achieved in six steps from homopiperonyl alcohol and 2-bromophenylacetonitrile by applying this catalytic tandem oxidation. Moreover, the direct conversion of xylopinine to 8-oxypseudopalmatine in a 76% yield demonstrates the versatility of this catalytic reaction.

Green synthesis technology of rotundine sulfate

The invention provides a green synthesis technology of rotundine sulfate. The green synthesis technology comprises the following steps: firstly, taking pyrocatechol as a starting reactant, and carrying out esterification, acylation and nitration; then carrying out deoxygenation reduction to obtain 3,4-dimethoxyphenethylamine; then carrying out condensation on the obtained 3,4-dimethoxyphenethylamine and 2,3-dimethoxy benzaldehyde and reducing to obtain (3,4-dimethoxy)phenethyl(2,3-dimethoxy)benzylamine; finally, carrying out cyclization, reduction and sulfation on the obtained (3,4-dimethoxy)phenethyl(2,3-dimethoxy)benzylamine, so as to obtain finished-product rotundine sulfate. The invention develops a full-synthesis technology taking the pyrocatechol as a raw material, and provides an environment-friendly, low-cost and high-yield green synthesis technology for synthesizing the rotundine sulfate.

A General, Concise Strategy that Enables Collective Total Syntheses of over 50 Protoberberine and Five Aporhoeadane Alkaloids within Four to Eight Steps

A concise, catalytic, and general strategy that allowed efficient total syntheses of 22 natural 13-methylprotoberberines within four steps for each molecule is reported. This synthesis represents the most efficient and shortest route to date, featuring three catalytic processes: CuI-catalyzed redox-A3 reaction, Pd-catalyzed reductive carbocyclization, and PtO2-catalyzed hydrogenation. Importantly, this new strategy to the tetracyclic framework has also been applied to the collective concise syntheses of >30 natural protoberberines (without 13-methyl group) and five aporhoeadane alkaloids.

HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The pr

HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.

Synthesis of alkaloids by stevens rearrangement of nitrile-stabilized ammonium ylides: (±)-laudanosine, (±)-laudanidine, (±)-armepavine, (±)-7-methoxycryptopleurine, and (±)-xylopinine

The Stevens rearrangement of nitrile-stabilized ammonium ylides in conjunction with the reductive removal of the nitrile function permits the facile construction of α-branched amines from α-aminonitriles. We employed this reaction sequence for the preparation of (±)-laudanosine, (±)-laudanidine and (±)-armepavine, (±)-7- methoxycryptopleurine, and (±)-xylopinine from two closely related and readily accessible bicyclic α-aminonitriles. The final products were obtained in high to almost quantitative yields (71-98%) from the quaternary ammonium salts obtained by N-alkylation of these starting materials.

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.